Faron Pharmaceuticals Ltd (LON:FARN) said early follow-up analysis of its unsuccessful phase III clinical trial suggests the treatment did not produce the expected interferon-beta bioactivity seen in the phase I/II study.
The company said it is still too early to understand why this was the case, but it cited a number of possible causes. It is investigating the formulation of the drug, its administration and deactivation.
READ: Faron Pharma assesses options after phase III disappointment
"Further detailed analysis of the data and testing of product batches still needs to be conducted, and therefore there is no guarantee that this will ultimately prove to be conclusive or, of the resultant implications of that analysis," Faron said in a short statement.